Donepezil, Galantamine, Rivastigmine and Memantine
|
|
- Henry Goodman
- 6 years ago
- Views:
Transcription
1 Donepezil, Galantamine, Rivastigmine and Memantine ESCA: For treatment of Alzheimer's disease AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of Donepezil, Galantamine, Rivastigmine and Memantine for Alzheimer s disease can be shared between the specialist and general practitioner (GP). GPs are invited to participate. If GPs are not confident to undertake these roles, then they are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. If a specialist asks the GP to prescribe this drug, the GP should reply to this request as soon as practicable. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care should be explained to the patient by the doctor initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. Patients with Alzheimer s disease are under regular specialist follow-up, which provides an opportunity to discuss drug therapy. The doctor who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. RESPONSIBILITIES and ROLES Specialist responsibilities This is an NHS Suffolk document that has been adopted by the WSCCG.
2 1 Confirm diagnosis of Alzheimer s disease. 2 Ask the GP whether he or she is willing to participate in shared care after a 16 week stabilisation period and discuss the agreement with the patient and carer. 3 Discuss benefits, side effects and prescribing guidelines of treatment with the patient and carer. The patient and carer should be prepared for any sudden deterioration that may occur when the drug is stopped. Ascertain willingness by the patient to take their medication and co-operation (within the bounds of their illness) with the assessment of their illness before treatment is initiated. Assurance of compliance may need to come from either the carer or care worker. 4 Assess donepezil, galantamine, rivastigmine or memantine dosage with particular reference to effectiveness in Alzheimer s disease. 5 Initiate donepezil, galantamine, rivastigmine or memantine treatment. 6 Communicate any changes in treatment with the GP promptly. 7 Monitor response to treatment. Treatment should only be continued where there has been an improvement or no deterioration in MMSE score or with evidence of global improvement on behavioural and/or functional assessment. An assessment of compliance should also be made at this stage. 8 Monitor cognition, behaviour and function unless the GP has agreed to do so. Advise the GP on frequency of monitoring & what to do when the parameters change. 9 An assessment by a hospital specialist will take place 6 months after the GP has agreed to prescribe. Continued assessment will be offered where the client and or their family have specific needs. 10 If necessary, supervise the withdrawal of treatment and provide supporting advice to the patient and carer. 11 Ensure clear back-up arrangements exist for GPs, including direct telephone helpline for advice and support. 12 Report adverse events to the CSM. General Practitioner responsibilities 1 After the four-month stabilisation period, any GP who is willing to accept the shared care agreement will notify the hospital specialist in writing, without undue delay, of their acceptance. 2 Prescribe donepezil, galantamine, rivastigmine or memantine at the dose advised by the specialist. 3 Receive and follow specialist advice on any changes in treatment. 4 Monitor the patient s general health and well being and liaise with the carer or care-worker as appropriate. 5 Seek specialist advice if the patient experiences adverse reaction/interaction or (for donepezil, galantamine or rivastigmine) MMSE drops below 10/30. 6 Refer back to specialist in the event of deteriorating clinical condition. 7 Report adverse events to specialist and CSM. 8 Keep mental health teams appraised of progress as appropriate and contact the specialist staff if there are any concerns or consider that the medication should be stopped. 9 If therapy has to be stopped, the specialist service must be contacted ASAP. Patient/Carer role 1 Report any adverse effects to the specialist or GP whilst taking donepezil, galantamine or rivastigmine. 2 Share any concerns in relation to treatment with donepezil, galantamine, rivastigmine or memantine with the specialist or GP. 3 Report to the specialist or GP if he or she does not have a clear understanding of their treatment. 4 Notify specialist services if the medication is stopped. BACK-UP ADVICE AND SUPPORT Suffolk Mental Health Partnership Trust Contact details Telephone No. Bleep: Fax: address: Specialist doctor Dr Gillian Collighan (East) Dr Anna King (East) Dr Sylvia Ferrera (West) Dr Ruth Chipperfield (West) Dr Judy Rubinsztein (West) Specialist nurse Annie Atkinson (East) Jane Polley (East) David Jarrold (West) Gillian.collighan@smhp.nhs.uk Anna.king@smhp.nhs.uk Sylvia.ferrera@smhp.nhs.uk Ruth.chipperfield@smhp.nhs.uk Judy.rubinsztein@smhp.nhs.uk Annie.atkinson@smhp.nhs.uk Jane.polley@smhp.nhs.uk David.jarrold@smhp.nhs.uk
3 Hospital Pharmacy dept SMHP Clinical Pharmacist (East) West Suffolk Hospital (West) Medicines Information bleep SUPPORTING INFORMATION Therapeutic review This shared care is based on revised guidance given by the National Institute for Clinical Excellence in March (Donepezil, Rivastigmine and Galantamine (review) and Memantine for the treatment of Alzheimer s disease. Available at NICE website: ). In summary, the review advises that donepezil, galantamine and rivastigmine are recommended as options for the treatment of mild to moderate Alzheimer s disease. Memantine is recommended as an option for people with moderately severe to severe Alzheimer s disease. A recommendation was made that if GPs were to be asked to supply these drugs, prescribing should be undertaken under a shared care document. The guidance did not assess the benefits of these drugs in non- Alzheimer dementias (such as dementia with Lewy bodies). Therefore this shared care guideline does not cover the treatment of these forms of dementia. A brief summary of Alzheimer s disease and its treatment Alzheimer s disease (AD) is the most common form of dementia although there are difficulties both with the diagnosis and with classification of the stages of the disease making exact patient numbers difficult to predict. It has been estimated that 26% of women and 21% of men over 85 years of age have some form of dementia, of which a little more than half have AD. Measurement tools for AD are imprecise but for cognitive outcome, MMSE (Mini Mental State Examination) scored out of 30 (best) and ADAS-cog (Alzheimer s disease Assessment Scale cognitive subscale) are commonly used. There are a number of other measures, which are primarily research tools. Mild AD is usually associated with an MMSE of 21 to 26. Moderate with an MMSE of and severe AD with an MMSE of less than 10. As AD progresses, acetylcholine (a neuronal transmitter) is produced in diminishing quantities. Donepezil, Galantamine and Rivastigmine all inhibit acetylcholinesterase, the enzyme that metabolises acetylcholine.
4 Memantine has a different mode of action. Memantine belongs to a group of medicines called NMDAreceptor antagonists. Memantine acts on these NMDA-receptors improving the transmission of nerve signals and the memory These drugs do not prevent the eventual outcome of the dementing process but merely postpone the onset of more severe impairment in a proportion of patients. Initial referrals under these guidelines may come from either GPs or another hospital specialist The referring doctor should screen the patient to exclude reversible causes of dementia. Recommended tests for screening dementia: FBC, Serum B12 & folate, U&Es, glucose, LFTs, TFT Ca 2+ (consider gamma GT if? alcohol problems, ESR/CRP, VDRL/TPHA, syphilis EIA), Where indicated urinalysis for Glucose/infection Referral should be made to the specialist memory clinics Donepezil, Galantamine or Rivastigmine (chosen according to specialist preference/experience), will be considered for patients whose mini mental state examination (MMSE) is between 10 and 26 (mild to moderate Alzheimer s disease). NOTE: The accuracy of the MMSE may vary for several reasons: for example, English as a foreign language, educational attainment, and sensory impairment. It may not be the most significant parameter in assessment for all individuals. In these circumstances, the clinician should have the flexibility to prescribe outside the score of A patient with Alzheimer s disease may be offered one of the other two drugs if the first is not tolerated or due to lack of clinical efficacy. Memantine will be considered for patients with moderate to severe Alzheimer s disease or for those with mild to moderate disease for whom acetylcholinesterases are contraindicated. Dosage and Administration Summary prescribing information for guidance only; please refer to the full SPC (available at local specialist or medicines information centre. Stopping Treatment Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms Patients who continue on treatment should be reviewed regularly using cognitive, global,functional and behavioural assessment. Treatment should be reviewed by an appropriate specialist team. Carers views on the patient s condition at follow-up should be sought.
5 Donepezil (Aricept ) Pharmacology Specific and reversible inhibitor of acetylcholinesterase Preparations available 5mg and 10mg tablets and orodispersible tablets. Licensed indications symptomatic treatment of mild to moderately severe Alzheimer s dementia Recommended dosage and administration 5mg once daily in the evening for at least one month, increasing after assessment to a maximum of 10mg once daily Contra-indications pregnancy and breast feeding Cautions - sick sinus syndrome and other supraventricular abnormalities, pts at risk of peptic ulcers, asthma, obstructive airway disease. Monitoring as per NICE guidance Drug interactions neuromuscular blocking agents, drugs with anticholinergic action, drugs that interact with P450 isoenzymes (such as quinidine, ketoconazole, itraconazole, erythromycin, rifampicin, phenytoin and carbamazepine (mainly in vitro studies). Adverse effects most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting, and insomnia Prescribing costs see table 1
6 Galantamine (Reminyl ) Pharmacology Competitive and reversible inhibitor of acetylcholinesterase, and also an enhancer of the intrinsic action of acetylcholine on nicotinic receptors. Preparations available 4mg, 8mg and 12mg galantamine tablets or modidified release capsules Licensed indications symptomatic treatment of mild to moderately severe dementia of the Alzheimer type Recommended dosage and administration Administer twice daily, preferably with morning and evening meals. Recommended starting dose is 4mg twice daily for four weeks, then maintenance with 8mg twice daily increasing after four weeks up to 12mg twice daily if required. Contra-indications severe hepatic or severe renal failure (as no safety data exists) Precautions sick sinus syndrome, supraventricular cardiac conduction abnormalities, patients at increased risk of peptic ulcers, severe asthma or obstructive pulmonary disease, urinary outflow obstruction, galactose intolerance. Pregnancy and lactation. Monitoring see NICE guidance Drug interactions cholinomimetic agents and muscle relaxants, paroxetine, ketoconazole, erythromycin, quinidine, fluoxetine, fluvoxamine, ritonavir all making side effects more likely Adverse effects Most commonly nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, anorexia, fatigue, dizziness, headache, somnolence and weight decrease. Prescribing costs see table 1
7 Rivastigmine (Exelon ) Pharmacology rivastigmine is an acetylcholinesterase inhibitor Preparations available 1.5mg, 3mg, 4.5mg and 6mg hard capsules and patch 9.5 mg/24 h Licensed indications Symptomatic treatment of mild to moderately severe Alzheimer s disease Recommended dosage and administration Administer twice daily with morning and evening meals. The capsules should be swallowed whole. The initial starting dose is 1.5mg twice daily. If this dose is well tolerated after a minimum of two weeks the dose may be increased to 3mg twice daily. Subsequent increases up to 4.5mg twice daily then 6mg twice daily may be considered after a further two weeks. The maximum daily dose is 6mg twice daily. Contra-indications severe liver impairment (no studies in these patients) Precautions sick sinus syndrome or conduction defects, patients at increased risk from peptic ulcer disease, patients with a history of asthma or obstructive pulmonary disease. Patients predisposed to urinary obstruction or seizures. Monitoring see NICE guidance Drug interactions succinylcholine-type muscle relaxants, other cholinomimetic drugs and anticholinergic medications. No other significant drug interactions have been observed. Adverse effects Asthenia, anorexia, dizziness, nausea, somnolence and vomiting. Female patients were found to be more susceptible to nausea, vomiting, loss of appetite and weight loss. Prescribing costs see table 1 Side Effects All suspected reactions (including those considered not to be serious and even where the causal link is uncertain) should be reported to the CSM. Monitoring Parameter Frequency of monitoring Action Cognition At initiation of treatment, at 4 months, at 10 months, and as a baseline prior to medication being stopped. Behaviour At initiation of treatment, at 4 months, at 10 months, and as a baseline prior to medication being stopped. ADL Function At initiation of treatment, at 4 months, at 10 months, and as a baseline prior to medication being stopped. Mini Mental State Examination, informant review Clinical Assessment, informant review Clinical Assessment, informant review
8 Memantine (Ebixa ) Pharmacology an NMDA receptor antagonist Preparations available 10mg and 20mg film coated tablets and 5mg/pump oral solution. Licensed indications Treatment of patients with moderate to severe Alzheimer's disease Recommended dosage and administration The maximum daily dose is 20 mg daily. In order to reduce the risk of undesirable effects the maintenance dose is achieved by upward titration of 5 mg per week over the first 3 weeks as follows: Week 1 (day 1 7): The patient should take one 5 mg tablet/half a 10 mg tablet/0.5 ml solution (5 mg) equivalent to one downward pump, per day for 7 days. Week 2 (day 8 14): The patient should take one 10 mg tablet/1 ml solution per day (10 mg) equivalent to two downward pumps, per day for 7 days. Week 3 (day 15 21): The patient should take one 15 mg tablet/one and a half 10 mg tablets/1.5 ml solution per day (15 mg) equivalent to three downward pumps, per day for 7 days. From Week 4 on: The patient should take one 20 mg tablet/two 10 mg tablets/2 ml solution per day (20 mg) equivalent to four downward pumps, once a day. Maintenance dose The recommended maintenance dose is 20 mg per day. A titration pack is also available Contra-indications Hypersensitivity to the active substance or to any of the excipients Cautions - Caution is recommended in patients with epilepsy, former history of convulsions or patients with predisposing factors for epilepsy. Concomitant use of N-methyl-D-aspartate (NMDA)-antagonists such as amantadine, ketamine or dextromethorphan should be avoided. These compounds act at the same receptor system as memantine, and therefore adverse drug reactions (mainly CNS-related) may be more frequent or more pronounced Monitoring as per NICE guidance Drug interactions ). Due to the pharmacological effects and the mechanism of action of memantine the following interactions may occur: The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dosage adjustment may be necessary. Concomitant use of memantine and amantadine should be avoided, owing to the risk of pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The same may be true for ketamine and dextromethorphan (see also section 4.4). There is one published case report on a possible risk also for the combination of memantine and phenytoin.
9 Other active substances such as such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels. There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is coadministered with HCT or any combination with HCT. Adverse effects most commonly constipation, hypertension, dyspnoea headache, dizziness and drowsiness Prescribing costs see table below Produced by Dr R Butler, Consultant Psychiatrist, SMHPT. Dr L Head, Consultant Psychiatrist, SMHPT. D Jarrold, Lead Nurse, Mental Health in Later Life, SMHPT. E Johnston, Head of Pharmacy Services, SMHPT April Table 1
EFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationEffective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine
Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationInterface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE
Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable
More informationShared Care Agreement for Donepezil, Galantamine, Rivastigmine and Memantine
Clinical SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: Date Treatment Started: Name of drug: (Add Date) One copy of information leaflet given to
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationDonepezil, Rivastigmine and Galantamine (TLS Amber with shared care) Donepezil (TLS green Wilts)
Donepezil, Rivastigmine and Galantamine (TLS Amber with shared care) Donepezil (TLS green Wilts) Shared Care Guidelines: For the treatment of Alzheimer s disease It is intended to apply to patients who
More informationTreatment of Alzheimer s disease
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Treatment of Alzheimer s disease Acetylcholinesterase
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationSHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline
POLICY UNDER REVIEW Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationSHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA
SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA Introduction Alzheimer s disease is the most common cause of dementia. It is characterised by an insidious onset of global mental
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationAricept, Exelon and Reminyl the new drugs for Alzheimer s disease
PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the
More informationReference Number MMG, GMW, NICE TA 217 Classification SHARED CARE PROTOCOL. Issue Date May 2011
SHARED CARE PROTOCOL for DONEPEZIL, GALANTAMINE, RIVASTIGMINE AND MEMANTINE in Dementia. SCOPE Greater Manchester West Mental Health NHS Foundation Trust NHS Salford NHS Bolton NHS Trafford Issue Date
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationPackage leaflet: information for the user. Memantine STADA 20 mg filmomhulde tabletten. Memantine hydrochloride
Package leaflet: information for the user Memantine STADA 20 mg filmomhulde tabletten Memantine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationEFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP.
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. The aim of an Effective Shared Care Agreement
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationDorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE
SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationNHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE
Suffolk Drug & Therapeutics Committee NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE What is a shared care document? Suffolk D&T operates a traffic light
More informationMelatonin Shared Care Agreement
For the treatment of sleep disorders in children with visual impairment or blindness, attention deficit hyperactivity disorder, autism (Unlicensed Use). Melatonin is licensed for the short term treatment
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationPATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an
More informationAREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
Effective Shared Care Agreement (ESCA) Midodrine ESCA: For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationPackage leaflet: information for the user. Marbodin 20 mg filmomhulde tabletten Memantine hydrochloride
Package leaflet: information for the user Marbodin 20 mg filmomhulde tabletten Memantine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationDementia Diagnosis & Disease Management in Primary Care
Dementia Diagnosis & Disease Management in Primary Care Service Level Agreement (SLA) 1 st April 2016 to 31 st March 2019 Contents: 1. Financial Details 2. Service Aims 3. Criteria 4. High Level Quality
More information0BCore Safety Profile
0BCore Safety Profile Active substance: Galantamine Pharmaceutical form(s)/strength: Film-coated tabl 4 mg, 8 mg, 12 mg Prolonged-release capsules, hard, 8 mg, 16 mg, 24 mg, Oral solution 4 mg/ml P-RMS:
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Memantine easypharm 10 mg, tabletten Memantine easypharm 20 mg, tabletten memantine hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Memantine easypharm 10 mg, tabletten Memantine easypharm 20 mg, tabletten memantine hydrochloride Read all of this leaflet carefully before you start taking this
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a
More informationMELATONIN Insomnia and Sleep Disorders in Children
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationShared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults
Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationShared Care Guidance. Vigabatrin
North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.
More informationDocument Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers
Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE PATIENT S NAME: PATIENT S ADDRESS: HOSPITAL NAME AND NUMBER /
More informationFulvestrant (Faslodex )
In Partnership with Health Authorities & GPs continuing-care guidelines Fulvestrant (Faslodex ) in the Management of Postmenopausal Women with Advanced Breast Cancer Approved by: Date approved: October
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationDrug treatments for Alzheimer s disease
Drug treatments for Alzheimer s disease Factsheet 407LP April 2018 There are no drug treatments that can cure Alzheimer s disease or any other common type of dementia. However, there are medicines for
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationTacrolimus (Adoport, Prograf, Modigraf or Advagraf )
Shared Care Guideline DRUG: Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) for Renal Transplant (Adults) Introduction: Indication: Prophylaxis of transplant rejection in kidney recipients Tacrolimus
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationS H A R E D P R E S C R I B I N G G U I D E L I N E
S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration
More informationDementia Care Pathway
Document level: West Locality Code: CC41 Issue number: 1 Dementia Care Pathway Lead executive Authors details Type of document Target audience Document purpose Medical Director Dr Anushta Sivananthan Dr
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationEssential Shared Care Agreement Naltrexone
In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy
More informationChild and Adolescent Mental Health Services (CAMHS)
Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER ARICEPT Evess 5 mg Orodispersible Tablets ARICEPT Evess 10 mg Orodispersible Tablets (Donepezil Hydrochloride) You and your caregiver should read all of this leaflet
More informationEFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation
Whipps Cross University Hospital NHS Trust EFFECTIVE SHARED CARE AGREEMENT July 2011 Dronedarone (Multaq ) For the treatment and management of atrial fibrillation INTRODUCTION The Whipps Cross University
More informationTransfer of Care Guidelines: Management of Dementia Drugs Process Summary
Transfer of Care Guidelines: Management of Dementia Drugs Process Summary Following assessment under EMDASS, patient is diagnosed with mild to severe Alzheimer s disease and is suitable for treatment with
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationShared Care Guideline Riluzole Treatment of Motor Neurone Disease
North Central London Joint Formulary Committee Shared Care Guideline Riluzole Treatment of Motor Neurone Disease Dear GP This shared care agreement outlines suggested ways in which the responsibilities
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationShared Care Agreement Apomorphine For use in Parkinson s Disease
Shared Care Agreement Apomorphine For use in Parkinson s Disease This shared care agreement outlines suggested ways in which the prescribing responsibilities can be shared between the specialist and GP.
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationMedication for Dementia (Acetylcholinesterase Inhibitors)
Medication for Dementia (Acetylcholinesterase Inhibitors) ^ ãéãäéê çñ `~ãäêáçöé råáîéêëáíó eé~äíü m~êíåéêë What are they? A group of medications used to help treat the symptoms of dementia in the mild
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationHydroxychloroquine (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationThe doctor/nmp who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use.
The 3T s Formulary NHS Swindon, NHS Wiltshire Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and Wiltshire Mental Health Partnership and Oxford Health NHS Foundation Trust) Shared
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More information